NX-5948, Nurix Therapeutics’ treatment for relapsed or refractory chronic lymphocytic leukemia, and Ga68-PentixaFor, Pentixapharm’s radiodiagnostic for primary aldosteronism, are the latest investigational products to secure a place on PRIME, the European Medicines Agency’s priority medicines scheme for drugs addressing unmet medical needs.
Key Takeaways
- NX-5948 and Ga68-PentixaFor are the latest entries on the PRIME scheme, bringing to 141 the total number of products to secure a place on the scheme.
- Asunercept, Apogenix’s drug candidate for glioblastoma, has been withdrawn from the scheme due to poor trial results.
- A total of 10 applications for a place on PRIME were denied in October and November, bringing to over 370 the number of applications that have so far been rejected
NX-5948 was among nine applications for a place on PRIME that the EMA’s human medicines committee, the CHMP, reviewed at its latest monthly meeting, which
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?